It is the first major partnership for the AIM-listed group, which will receive US$10mln up front and a further US$284mln dependent on how successful the drug proves.
READ: C4X Discovery expects “significant progress” in 2018 as it looks for a partner to take its addiction drug through the clinic
Markets had been waiting for C4X to agree a sizeable licensing deal and Clive Dix, chief executive, said the Indivior agreement validates both its strategy and its drug discovery platform.
In particular, it highlighted how C4X’s drug discovery engine “can generate best-in-class small-molecule candidates in high-value therapeutic areas”.
Taken orally, C4X3256 is seen as a new way of treating addiction and related disorders as it targets only the brain’s Orexin-1 receptor, which is considered central to a person’s craving and reward pathways.
Through the licence, Indivior receives global and exclusive rights to C4X3256 and all other compounds in the same patent family.
In return, it will carry all of the costs for its future development.
The agreement covers the development of Orexin-1 antagonists for multiple indications, said C4X.
Dix added: “This agreement will allow us to accelerate the development of our portfolio to similar successful commercial arrangements."